Epstein–Barr Virus and gastric carcinoma pathogenesis with emphasis on underlying epigenetic mechanisms Authors: Fatemeh Estaji, Saeed Zibaee, Maryam Torabi, Sharareh Moghim Published: 2024 ABSTRACT AbstractGastric cancer (GC) remains one of the top causes of cancer-related mortality around the world. The pathogenesis of GC is attributed to lifestyle, family history, genetic mutations, epigenetic alterations, as well as infectious agents such as Epstein–Barr Virus (EBV). EBV, a ubiquitous human gamma herpes virus, with latent asymptomatic infection in more than 95% of the world’s population, is able to infect through the oral epithelium. EBV is described as the first virus found in human neoplastic, when it was detected in Burkitt lymphoma tumor biopsy. Nowadays this virus is considered to be involved in various human malignancies such as GC. Despite comprehensive efforts and immense studies, the main underlying mechanism is not well described as there are crucial contradictions regarding the presence of this virus and the prognosis of the disease. Immunological alterations, genetic mutations, and epigenetic modifications are among the most important criteria presented in EBV- associated gastric cancer (EBVaGC), leading to its consideration as a separate subtype with unique clinical, histological, biochemical, and genetic characteristics. The current study aimed to review the association between EBV and GC with an emphasis on the role of epigenetic modifications in the suppression or progression of carcinogenesis. To put all findings in a nutshell, several genes and chromatin mutations, promoter hypermethylation and subsequent silencing of related genes, and histone modifications and aberrant micro RNAs (miRNAs) expression were considered as the major altered mechanisms in the pathogenesis of EBVaGC, most of which able to be suggested as therapeutic targets. However, the current knowledge appeared to be imperfect, hence further studies are encouraged.Keywords: Epstein–Barr Virus, Epigenetic, Hypermethylation, miRNA, Histone, EBV associated gastric cancer Introduction Gastric cancer (GC) is considered the second cause of cancer-related mortality and the fourth most common cancer around the world [1, 2]. According to recent statistics, more than one million individuals have been diagnosed with GC, which is caused approximately 770,000 subsequent deaths globally [3]. Unfortunately, although some remarkable advancements have occurred, multiracial benchmarking investigations have revealed that GC survival rates remain low, even in most developed countries which in turn demonstrates that a strong focus on preventive approaches is highly required [3, 4]. The treatment strategy is usually a combination of surgical resection of the tumor and chemotherapy [5, 6], although adverse effects of chemotherapy must be considered [7]. Despite of significant decline in the incidence of GC and its mortality in most countries for several decades due to better food preservation and economic development, recent findings indicate a remarkable increase in incidence rates, particularly in young adults who are less than fifty years old [8, 9]. Topographically, GC could be divided into two separated subsites including a: cardia GC which is arisen from the area of the stomach adjoining the esophagogastric junction, and b: non-cardia involvement GC which is believed to have risen from more distal regions of the stomach [3, 10]. Continuous studies have considered various types of risk factors, including unhealthy lifestyle (e.g. smoking, heavy alcohol consumption, salting foods), family history [11], underlying chronic diseases (e.g. gastritis, insomnia, obesity) [12–14], genetic aberrations (e.g. gene mutations and chromosomal aberrations) [15, 16], epigenetic alterations (e.g. DNA hypermethylation and histone deacetylation) [17–20], and infectious agents eighter bacterial or viral [21, 22] as risk factors for causing GC. Helicobacter pylori (H. pylori ) is considered as a major risk factor for GC. H. pylori causes approximately 80% of the GC worldwide [23]. The carcinogenic mechanism of H. pylori has been investigated and two possible ways have been suggested: direct interaction of the bacteria with the stomach epithelium through virulence factors such as cagA and vacA. The indirect mechanism through induction of chronic active inflammation which can eventually lead to gastric cancer [24]. One of the most important virulence factors of pathogenicity island bacteria is cag (cag PAI), which encodes the type 4 secretion system (T4SS) and sends the effector protein CagA into host cells [25]. CagA has several effects on epithelial cells, activate the inflammatory signaling [26]. The host cell’s response against this protein increases cell motility and enhances epithelial cell junctions and pro-inflammatory responses related to the development of chronic gastritis and stomach cancer. VacA has the potential to form intracellular vacuoles, may play a role in the oncogenic potential of H. pylori [27]. The simultaneous infection of H. pylori and EBV can occur in gastric cancer and may have a synergistic effect in gastric carcinogenesis. It is said that two possible mechanisms are possible in carcinogenesis. First, a stronger inflammatory response in coinfection that causes more severe tissue damage. And the second mechanism is based on the effects of the gene products of these two pathogens, which is more important [23]. Both H. pylori and EBV are able to induce epigenetic changes in target cells that lead to oncogene activation or tumor suppressor gene silencing, increasing the risk of malignancy [27]. Further investigation must be done to clarify the mechanism of H. pylori and EBV coexistence in GC. DNA hypermethylation, particularly in promoter CpG islands contributes to the silencing of tumor-suppressor genes and hence results in gastric carcinogenesis, as well as other molecular aberrations such as aberrant chromatin structures, structural variants, somatic copy number alterations, and gene mutations are involved in gastric tumorigenesis [28]. Recent advances in high-throughput technologies have been revealing an intricate network of genetic and epigenetic alterations that contribute to tumorigenesis. Furthermore, both environmental and genetic risk factors have been recognized to be capable of promoting the accumulation of varied alterations affecting the expression and levels of oncogenes, tumor-suppressor genes, DNA repair systems, etc [29]. It is documented that phenotypically GC represents different signatures, thus Cancer Genome Atlas has classified it into at least four different subtypes including gnomically stable, microsatellite instability, chromosomal instability, and Epstein–Barr Virus (EBV) [30]. In addition, comprehensive analyses of DNA methylation have suggested that GC could be classified into three different epigenetically subgroups according to the DNA methylation patterns including extremely high-methylation epigenotypes which are uniquely reported in EBV-positive GC, high methylation epigenotypes which are caused by microsatellite instability, and low methylation epigenotypes [31, 32]. Among the whole human malignancies, EBV-positive GC represents the most extreme rates of hypermethylation mostly attributed to the silencing of CDKN2A, overexpression of PD-L1/2, mutations associated with PIK3CA, and lack of TP53 mutations, and mutations in other genes, for example, ARID1A, CDH1, KRAS, SMAD4, APC, CTNNB1, PIK3CA, etc [28, 33]. More importantly, the high frequent incident of characteristic CpG island methylator phenotypes in GC, specifically related to the EBV infection, is suggested as a presentation of epigenetic modulators into standard therapeutic approaches which is beneficial against both early and advanced types of adenocarcinomas [34]. Thereby, understanding the epigenetic mechanisms associated with the incidence of GC can introduce practical strategies for both prevention and treatment of the disease. Furthermore, GC caused by EBV is considered one of the most common forms of this disease. Hence, the present study aimed to review the current knowledge about EBV-induced epigenetic alterations related to gastric carcinogenesis and progression. In this regard, this study first introduces EBV and its subsequent effects on GC, then the role of related epigenetic changes induced by EBV is discussed. A concise introduction to EBV and its pathogenicity EBV is a ubiquitous human gamma herpes virus, consisting of 184 kb of double-stranded DNA, with latent asymptomatic infection in more than 95% of the world’s population [35]. EBV is able to infect through the oral epithelium where the virus primarily replicates and generates viral progeny [36]. The primary asymptomatic infection mostly occurs during early childhood, howbeit delayed exposure to EBV could affect young adults by acute infectious mononucleosis [37]. The particles of this virus can infect naïve B-cells and cause latency mimicking physiological B-cell maturation via the germinal center-like reaction [38, 39]. In addition, this virus persists constantly in the memory B-cell pool in which any immunosuppression or concurrent HIV infection could be followed by the development of B-cell malignancies [40, 41]. Importantly, EBV-related tumors account for a high number as 2% of the worldwide cancer death burden [42]. EBV is considered the first virus detected in human neoplastic as it was found in 1964 in the Burkitt lymphoma tumor biopsy [43] and currently it is believed to be involved in various human malignancies with origins of eighter epithelial or lymphoid cells such as GC, nasopharyngeal carcinoma, Burkitt’s lymphoma, Hodgkin lymphoma, post-transplant lymphoproliferative disease, natural killer-cell/T-cell lymphoma, and certain B-cell and T-cell lymphomas [44]. Notably, EBV is associated with approximately 100% of nasopharyngeal carcinoma cases [45]. Epstein–Barr virus has two distinct phases in its life cycle: the lytic phase and the latent phase. In latent infection, the genomic DNA of the virus is present in episome form which can reproduce simultaneously with the host genome. In some special conditions, this virus can enter the lytic cycle where the production of infectious virions occurs. B cells are the initial targets of EBV [46]. The de novo. infection by EBV is extensively investigated in B cells by a variety of studies. It is well documented that upon initial infection, B-cells proliferation is enhanced uncontrollably by viral latency proteins resulting in the transformation into lymphoblastoid cells [47]. The virally encoded latent proteins, including 6 EBV nuclear antigens which are EBNAs 1, 2, 3 A, 3B, 3 C, and –LP, as well as 3 latent membrane proteins which are LMPs 1, 2 A, and 2B, are expressed by the infected B-cells in a state that is called latency III [48, 49]. Subsequent to the initial infection of these immunological cells, the nuclear antigens, EBNA-LP and EBNA2, are expressed as transcriptional activators which activate other EBNA genes finally leading to the expression of LMPs [47]. Considerably, most of these genes are pivotal for B-cells’ immortalization. In addition, non-coding RNAs, the most important of which are EBER1 and EBER2, are expressed [44]. Along with that, forty-four microRNAs (miRNAs) are expressed from the BamHI A rightward transcripts and the BHRF1 locus, known as BART and BHRF1miRNAs [50, 51]. Although during latency III and initial infection of B-cells, all of the mentioned latency proteins and long and short RNAs are expressed, in other tumor types and latently-infected cells more restricted gene expression patterns are displayed. EBV is associated with GC The first discovery of EBV-associated GC resulted from a polymerase chain reaction in a lymphoepithelioma gastric tumor in 1990, and nowadays it has been detected in approximately 10% of GC cases worldwide [52, 53]. Despite this established statistic, EBV-positive GC exerts the largest worldwide death burden among all EBV-positive cancers. Although GC is known to be more dominant in Asian countries, EBV-positive tumors are not restricted or specified to any geographic area. However, Asian countries exert the most abundant global burden of death caused by EBV-positive malignancies [42, 54]. EBV-positive GC exerts a limited latency I gene expression pattern as only a few crucial genes, including EBNA1, the BART miRNAs, EBERs, and occasionally LMP2A, are expressed [55–57]. EBNA1, which is responsible for the attachment of EBV episomes to host chromosomes, is expressed in all latency phases as well as in all infected cells. Furthermore, EBNA1 is able to act as a transcriptional regulator that binds to viral promoters including its promoter leading to self-regulation [58–60]. In addition, the BART miRNAs are frequently expressed in latency I neoplasms and tumors with the epithelial origin that are capable of promoting tumor growth in vivo [61]. Along with that, it has been demonstrated that the BART miRNAs can inhibit apoptosis via interactions with pro-apoptotic proteins, hence enhancing epithelial cell survival [62, 63]. LMP2A is expressed in approximately half of the epithelial tumors and could increase the tumorigenesis ability through upregulation of DNA methyltransferase 1 (DNMT1) and increasing CpG island methylation of tumor suppressor promoters [53, 64]. It is revealed by the monoclonal EBV episomes in the tumors the infection potentially occurs primarily in tumor development. Moreover, It is suggested by the restricted latency program that additional oncogenic factors are likely involved in tumor development [47]. As mentioned earlier, GC is divided into different subtypes according to a variety of classifications based on histologic, genotypic, phenotypic, and clinicopathological characteristics [65, 66]. EBV-positive GC, for example, is a distinct subtype of gastric tumors when compared to EBV-negative cancers that are divided into three additional subtypes [67]. Genomically, high mutation rates of PIK3CA and ARID1A are exclusive mutational profiles related to EBV-positive GC [68]. In addition, extreme DNA hypermethylation of tumor suppressor promoters is the epigenetic feature of EBV-positive GC [47, 69]. Along with this unique molecular profile, EBV-positive cancers are usually detected in the fundus or body of the stomach, which is described as. a characteristic histologic appearance of EBV-positive GC [70, 71]. Despite all of these different classifications, the present study reviews EBV-positive GC with an emphasis on induced epigenetic alterations. EBV infection leads to gastric tumor via epigenetic modifications The present study in the previous sections clearly illustrated that genotypically the EBV-positive GC is a separate subtype with unique diagnostic, prognostic, and treatment characteristics. In the following, this study will divide the conducted investigations regarding EBV-induced molecular alterations associated with GC into three subheadings including gene and chromatin mutations, gene hypermethylation, and histone deacetylation, and review them separately. Gene and chromatin mutations It is documented that three-dimensional (3D) chromatin organization exerts a crucial role in the regulation of gene expression as the aberrant 3D chromatin topologies have been associated with cancer occurrence [72]. In GC, a valuable study by Okabe et al. with genome-wide analysis of 3D chromatin topologies suggested chromatin domains specific to EBV-positive GC represent long-range interactions between the host and virus with non-integrated EBV episomes as well as heterochromatin-to-euchromatin transitions. Moreover, the study revealed that EBV is able to remodel chromatin topology, convert H3K9me3+ heterochromatin to H3K4me1+/H3K27ac+ bivalency, and promote latent enhancers to activate nearby GC-related genes such as TGFBR2 and MZT1, resulting in the facilitation of proto-oncogene activation and tumorigenesis [59]. A whole-genome and transcriptome sequencing study on 50 patients with EBV-positive GC demonstrated that a frameshift mutation in the ASTE1 gene was responsible for triggering the immune response suggesting that GC infected with EBV is accompanied by increased expression. of immune response genes and ample immune infiltration [73]. Similarly, a whole-genome, transcriptome, and epigenome sequence analyses in a gastric adenocarcinoma cell line and patient samples revealed that EBV caused non-synonymous mutations in several genes including CCNA1, AKT2, MAP3K4, and TGFBR1, which were associated with reduced survival times and dysregulate MAPK signaling [74]. Promoter hypermethylation EBV-positive GC mostly exhibits a desirable prognosis when compared to EBV-negative cases due to hypermethylation of both viral and host genes, along with a remarkable immune cell infiltration. The promoter hypermethylation, for example, results in the downregulation of IL-15 receptor α in EBV-positive GC [75]. In this regard, Wei et al. demonstrated that in EBV-negative GC and thereby the lack of hypermethylation of the IL-15 receptor α promoter, this cytokine is highly expressed resulting in its expression on the surface of cancer cells which is followed by a malignant phenotype compromising of augmented cell growth, invasion, and migration, as well as enhanced cell survival and reduced lymphocytes infiltration due to alterations in STAT1, STAT3, and ERK1/2 pathways [76]. Furthermore, it is documented that GC infected with EBV is accompanied by deregulation of MHC-class II and chemokine activity regulatory genes through epigenetically alterations that resulted in recruiting reactive immune cells and better outcomes [77]. However, transcriptomic and epigenomic analyses by Fiches et al. demonstrated that hypermethylation results in the silencing of immune-related genes such as metallothionein-1 and homeobox A gene clusters. These immune-related genes are involved in the suppression of EBV lytic replication and release of progeny virions, as well as antiviral activities. Thereby, the authors described the silencing of mentioned genes through hypermethylation as a viral strategy to evasion. immune surveillance and enhance viral propagation, hence promoting viral oncogenesis [78]. Similarly, hypermethylation of the distal promoter of interferon regulatory factor-5 is described as an advantage for EBV carcinogenesis in GC [79]. Furthermore, a genome-wide high-resolution array on 157 patients who received surgery for GC revealed that hypermethylation of FLI1, ADAM19, and MSC genes in EBV-positive samples was associated with advanced GC, distant lymphatic metastasis, and worse 5-year disease-free survival [80]. In addition, the silencing of tumor suppressor genes through hypermethylation of enhancer regions resulted in the dysfunction of tumor suppressive pathways and activation of cancer hallmarks pathways such as promoted cancer cells survival, disrupting cellular energetics, enhanced invasion, angiogenesis, sustaining proliferative signaling, and tumor-promoting inflammatory cascades [81]. The hypermethylation of the promoter region of the cylindromatosis (CYLD) gene, which is a tumor suppressor deubiquitinase that negatively regulates several signaling pathways such as Wnt, Shh, Notch, JNK, hence affecting the fundamental cell processes such as apoptosis, immune response, and cell cycle progression, was reported in EBV-positive GC samples resulting in the downregulation of this gene and higher grades of disease [82]. Aberrant gene promoter hypermethylation of p16, FHIT, WWOX, CRBP1, and DLC-1 has been related to the development of EBV-positive GC [83]. The hypermethylation of gene promoters of EBV latent membrane proteins 1, 2 A, and 2B resulted in the silencing of these genes and subsequent carcinogenesis, a phenomenon which could be alleviated by demethylation agents, suggesting a novel therapeutic target [84]. Liang et al. demonstrated that EBV-induced hypermethylation of ACSS1, IHH, FAM3B, and TRABD genes in a gastric adenocarcinoma cell line, as well as patient samples, resulted in the increased proliferation and colony formation of GC cells [74]. Moreover, epigenetic silencing of WNT5A in EBV-positive GC is caused via promoter hypermethylation [85]. REC8 has been described a novel. tumor-suppressor gene that is silenced via promoter hypermethylation in EBV-positive GC, causing shortened survival of GC patients [86]. In addition, CpG promoter gene hypermethylation of somatostatin receptor 1 in EBV-positive GC contributes to GC pathogenesis through the promotion of G1 to S-phase transition, enhancing cell proliferation and colony formation ability, and raising cell migration and invasive ability [87]. Histone modifications and miRNAs regulation It is well established that EBV-induced histone modifications could be altered dynamically and coordinately with DNA hypermethylation. Funata et al., for example, have revealed that EBV-induced loss of H3K27me3 marks or reduction in H3K4me3 and H3K27ac, active histone marks, was accompanied by the promoter of several DNA methylation-sensitive genes, followed by repression of apoptosis and genes related to DNA repair systems [88]. An interesting study in gastric epithelial cells infected with EBV by Okabe et al. revealed that along with genes hypermethylation, histone modifications on H3K4me1, H3K4me3, H3K27me3, H3K27ac, and H3K9me3 resulted in the silencing of tumor suppressive genes which was followed by dysfunction of tumor-suppressive pathways and activation of tumor hallmarks [81]. Contrary to histone modifications which are documented to be accompanied by DNA hyper methylation, Kase et al., suggested that ARID1A deficiency in clinical GC samples of EBV-positive GC was caused by posttranscriptional gene silencing via miR-BART11-3p and miR-BART12 overexpression instead of DNA promotor hyper methylation [89]. However, WIF1, NLK, and APC genes are reported to be highly methylated in EBV-positive GC, in which their expression is regulated by miR-BART19-3p enhances cell growth remarkably [90]. miR-BART4 is considered the most prevalent EBV-miRNA in EBV-positive GC, followed by miR-BART11, miR-BART2, miR-BART6, miR-BART9, and miR-BART18, respectively. Nevertheless, miR-BART9 exhibited the most important effects during carcinogenesis [91]. Accordingly, miR-129-2-3p, which is able to target AKAP12 and LARP6, is downregulated in EBV-positive GC samples along with other biochemical, immunological, and genetic alterations [92]. Conclusion To put all findings in a nutshell, it is well established that EBV could be a causative agent in GC pathogenesis, assumed as a distinct subtype of gastric carcinogenesis distinguished by unique histological and genetic/epigenetic properties, which is capable of consideration as a prognosis biomarker and therapeutic target. Epigenetic modification, such as genes and chromatin mutations, hypermethylation, histone modification, and miRNAs levels is described as the main underlying mechanisms in EBV-induced GC. Nevertheless, there are some contradictions regarding the coincidence of DNA hypermethylation with histone modifications and with miRNAs expression as well as EBV-induced alterations in immunological responses and its effects on disease prognosis that are required to be clearified by further studies. Acknowledgements The authors hereby appreciate the Isfahan University of Medical Sciences for their support during the investigations. Author contributions FE: data collection, writing—original draft. SZ: data curation. MT: data curation. SM: study conceptualization, database curation; funding acquisition; project supervision; validation; writing—review and editing. Funding This work was funded by Isfahan University of Medical Sciences [Grant number: 396765]. Data availability No datasets were generated or analysed during the current study. Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement No datasets were generated or analysed during the current study.